Reply

Affiliations

¹ The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
² Institute of Immunology and Immunotherapy, National Institute for Health Research Biomedical Research Centre IBD Theme, Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom.

Comment

Robert P Hirten et al. Clin Gastroenterol Hepatol. 2019 Mar.

. 2019 Mar;17(4):796-797.

doi: 10.1016/j.cgh.2018.08.056.

¹ The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
² Institute of Immunology and Immunotherapy, National Institute for Health Research Biomedical Research Centre IBD Theme, Institute of Translational Medicine, University of Birmingham, Birmingham, United Kingdom.

No abstract available

Comment on

Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.
Hirten RP, Iacucci M, Shah S, Ghosh S, Colombel JF. Hirten RP, et al. Clin Gastroenterol Hepatol. 2018 Sep;16(9):1374-1384. doi: 10.1016/j.cgh.2018.02.024. Epub 2018 Mar 2. Clin Gastroenterol Hepatol. 2018. PMID: 29481970 Review.
Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.
Le Berre C, Loeuille D, Peyrin-Biroulet L. Le Berre C, et al. Clin Gastroenterol Hepatol. 2019 Mar;17(4):794-796. doi: 10.1016/j.cgh.2018.08.017. Epub 2018 Aug 13. Clin Gastroenterol Hepatol. 2019. PMID: 30114486 No abstract available.